FGFR3 and central nervous system cancer: Following on from the promising clinical results achieved by one of these compounds, infigratinib (BGJ398) in metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements (70), a phase I study (NCT04424966) is ongoing in recurrent high-grade glioma with definite mutations of FGFR1 or FGFR3 or translocations involving FGFR3 (14).